Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

NCT00188617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

LUNG CANCER

Interventions

DRUG: GEFITINIB

Sponsor

University Health Network, Toronto

Collaborators

[object Object]